Chlorambucil for patients with primary biliary cirrhosis

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 9, 2012, Pages

  Li, Wei Xin ^a   Yan, Xiang ^a   Shi, Chun Rui ^a   Zhang, Ai Ping ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; IMMUNOSUPPRESSIVE AGENT;

BILIARY CIRRHOSIS; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

CHLORAMBUCIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84873034923     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008714.pub2     Document Type: Article

References (65)

1. Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986;91(6):1327-34.
2. Hoofnagle JH, Davis GL, Schafer DF, Peters MG, Avigan MI, Hanson RG, et al. Randomized trial of chlorambucil for primary biliary cirrhosis [AASLD abstract]. Hepatology 1984;4(5):1062.
3. Kaplan MM. Another treatment for primary biliary cirrhosis. Gastroenterology 1987;92(1):255-7.
4. Alempijevic T, Krstic M, Jesic R, Jovanovic I, Sokic Milutinovic A, Kovacevic N, et al. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World Journal of Gastroenterology 2009;15(5):591-4.
5. Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Medical Research Methodology 2003;3:16.
6. Bergasa NV. The pruritus of cholestasis. Journal of Hepatology 2005;43(6):1078-88.
7. Cannon GW, Jackson CG, Samuelson CO Jr, Ward JR, Williams HJ, Clegg DO. Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. Seminars in Arthritis and Rheumatism 1985;15(2):106-18.
8. Chisesi T, Congiu M, Contu A, Coser P, Moretti L, Porcellini A, et al. Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: an interim report of a randomized study. Non-Hodgkin's Lymphoma Cooperative Study Group. European Journal of Cancer 1991;Suppl 4:31-3.
9. Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985;89(5):1084-91.
10. Clements P, Lachenbruch P, Furst D, Paulus H. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis and Rheumatism 1993;36(11):1575-9.
11. Dickson ER, Fleming TR, Wiesner RH, Baldus WP, Fleming CR, Ludwig J, et al. Trial of penicillamine in advanced primary biliary cirrhosis. New England Journal of Medicine 1985;312(16):1011-5.
12. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10(1):1-7.
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
14. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. Journal of Immunology 1987;138(10):3525-31.
15. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 2008;47(2):737-45.
16. Giljaca V, Poropat G, StimacD, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD004385.pub3]
17. Gluud C. Mortality from cirrhosis: lack of progress over the last 35 years. Gut 2005;54(11):1523-6.
18. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2012, Issue 2. Art. No.: LIVER.
19. Goldblatt J, Taylor PJ, Lipman T, Prince MI, Baragiotta A, Bassendine MF, et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002;122(5):1235-41.
20. Gong Y, Klingenberg SL, Gluud C. D-penicillamine for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004789.pub2]
21. Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD004481.pub2]
22. Gong Y, Christensen E, Gluud C. Cyclosporin A for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD005526.pub2]
23. Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006000.pub2]
24. Gong Y, Huang ZB, Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD000551.pub2]
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557-60.
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
27. Hoofnagle JH, Davis GL, Schafer DF, Peters MG, Avigan MI, Hanson RG, et al. Randomized trial of chlorambucil for primary biliary cirrhosis [AASLD abstract]. Hepatology 1984;4(5):1062.
28. Hughes GS Jr, Kataria YP, O'Brien TF Jr. Sarcoidosis presenting as biliary cirrhosis: treatment with chlorambucil. Southern Medical Journal 1983;76(11):1440-2.
29. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
30. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997;25(5):1090-5.
31. Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Internal Medicine 2011;50(1):1-10.
32. Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis 1991;8(1):35-41.
33. Johnson SA, Owen RG, Oscier DG, Leblond V, Levy V, Jaeger U, et al. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. Clinical Lymphoma 2005;5(4):294-7.
34. Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 1991;101(5):1332-8.
35. Kaplan MM. The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Seminars in Liver Disease 1997;17(2):129-36.
36. Kaplan MM. Primary biliary cirrhosis: past, present, and future. Gastroenterology 2002;123(4):1392-4.
37. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. New England Journal of Medicine 2005;353(12):1261-73.
38. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. American Journal of Gastroenterology 2009;104(3):546-51.
39. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36(1):227-42.
40. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
41. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 2009;27(26):4378-84.
42. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, et al. Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. British Journal of Haematology 2000;108(4):737-42.
43. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009;50(1):291-308.
44. Miller E. The use of cytotoxic agents in the treatment of immune-mediated diseases of dogs and cats. Seminars in Veterinary Medicine and Surgery (small animal) 1997;12(3):157-60.
45. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. Journal of Hepatology 1992;15(3):336-44.
46. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
47. Nand N, Das R, Jaswal TS. Evaluation of efficacy of methylprednisolone, prednisolone and chlorambucil in idiopathic glomerulonephritis. Journal of the Indian Medical Association 1997;95(6):163-5, 174.
48. Neuberger J, Christensen E, Portmann B, Caballeria J, Rodes J, Ranek L, et al. Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. Gut 1985;26(2):114-9.
49. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatric Nephrology 1992;6(1):1-3.
50. Pasha TM, Dickson ER. Survival algorithms and outcome analysis in primary biliary cirrhosis. Seminars in Liver Disease 1997;17(2):147-58.
51. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney International 1995;48(5):1600-4.
52. Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Hepatology 1996;24(5):1098-103.
53. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004;53(6):865-70.
54. Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD003778.pub2]
55. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
56. Robak T, Bloński JZ, Kasznicki M, Blasińska-Morawiec M, Krykowski E, Dmoszyńska A, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96(8):2723-9.
57. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
58. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
59. Senn HJ, Maibach R, Castiglione M, Jungi WF, Cavalli F, Leyvraz S, et al. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil - 11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. Journal of Clinical Oncology 1997;15(7):2502-9.
60. Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: High prevalence in migrant populations. Gastroenterology 2004;127(2):470-5.
61. Tattersall MH, Swanson CE, Solomon HJ. Long-term survival with advanced ovarian cancer: an analysis of 5-year survivors in the Australian trial comparing combination versus sequential chlorambucil and cisplatin therapy. Gynecologic Oncology 1992;47(3):292-7.
62. Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotlandand Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia & Lymphoma 2006;47(11):2321-30.
63. Verma A, Jazrawi RP, Ahmed HA, Northfield TC. Prescribing habits in primary biliary cirrhosis: a national survey. European Journal of Gastroenterology & Hepatology 1999;11(8):817-20.
64. Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. New England Journal of Medicine 1990;322(20):1419-24.
65. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.